Shire has hinted that a spinoff of its neuroscience unit may be in the works. But one U.S. hedge fund wants more.
Sachem Head Capital Management, which nabbed a small Shire stake over the summer, is demanding a list of divestments at the Dublin drugmaker, the U.K.’s Sky News reports.
The fund, founded by Bill Ackman protégé Scott Ferguson, hasn’t yet formally penned a letter to the company’s board, but it’s raised the possibility of a larger breakup during discussions with Shire in recent months, Sky’s sources say.
Sachem Head’s urging comes during a rocky period for Shire shares, which have taken a beating since the company doled out $32 billion for hemophilia specialist Baxalta. While executives have touted the merger’s success—and Shire’s progress toward a $700 million cost-savings target—“neither markets nor employees seem as confident as management that things are on track,” UBS analysts wrote in August as they slashed their 12-month price target.
And speaking of executives, their ranks at Shire have thinned recently with the departures of R&D chief Phil Vickers and CFO Jeff Poulton—and those exits haven’t helped shares, either. “The timing is highly inopportune and serves to exacerbate already negative investor sentiment,” Jefferies analyst David Steinberg wrote to clients after the Poulton announcement in August.
Shire has signaled that it may be down for at least a little bit of move-making, revealing in August that it’s “assessing strategic options” for the neuro franchise, which includes the company’s flagship ADHD products. The Irish pharma expects its evaluation to wrap by year’s end.
Meanwhile, divestments across the pharma industry continue. Pfizer last week said it’s considering selling off its consumer health unit, and AstraZeneca has notably been selling off drug rights and striking partnerships as it focuses on its core goals.
By Carly Helfand
Source: Fierce Pharma
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
